Therapeutic Options and Treatment Strategies Against COVID-19 in China

Author(s): Zhiwei Miao, Yan Cai, Jing Meng, Weihong Zhou

Journal Name: Current Organic Synthesis

Volume 17 , Issue 6 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Tu, Y.; Chien, C.; Yarmishyn, A-A.; Lin, Y.; Luo, Y.; Lin, Y.; Lai, W.; Yang, D.; Chou, S.; Yang, Y-P.; Wang, M-L.; Chiou, S-H. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 2020, 21, 2657-2676.
[2]
Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov., 2020, 19(3), 149-150.
[3]
De Clercq, E.; Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev., 2016, 29, 695-747.
[4]
Elfiky, A-A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci., 2020, 248 117477
[5]
Sheahan, T-P.; Sims, A-C.; Leist, S-R.; Schafer, A.; Won, J.; Brown, A-J.; Montgomery, S-A.; Hogg, A.; Babusis, D.; Clarke, M-O.; Spahn, J-E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J-Y.; Cihlar, T.; Jordan, R.; Denison, M-R.; Barici, R-S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 2020, 11(222), 1-14.
[6]
Gao, J.; Tian, Z.; Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends, 2020, 14(1), 72-73.
[7]
Abd El-Aziz, T-M.; Stockand, J.D. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infec.Gen. Evol., 2020, 83 104327
[8]
Chen, X-J.; Tian, J-Z.; Li, G-M.; Li, G-W. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis., 2020, 20(4), 398-400.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 6
Year: 2020
Published on: 24 September, 2020
Page: [413 - 414]
Pages: 2
DOI: 10.2174/157017941706200925091306

Article Metrics

PDF: 21
HTML: 2